Einzeltreffer — DigiBib

Pembrolizumab is an anti-cancer drug that targets programmed cell death protein-1 (PD-1) receptors on lymphocytes resulting in their activation against tumour cells. PD-1 receptors are also interspersed in endocrine organs and pembrolizumab use has long been associated with hypophysitis and thyroiditis. Since the introduction of immune checkpoint inhibitors (ICI), several cases of fulminant type 1 diabetes mellitus (FT1DM) have been reported. However, it is unclear if FT1DM and ICI-induced diabetes are the same pathology. We review the existing literature of ICI-induced diabetes to investigate its nature and to what extent it represents type 1A diabetes and/or FT1DM (type 1B diabetes) using an example case. Our review showed that ICI-induced diabetes may be a different entity to FT1DM. Furthermore, there is limited evidence for the management of ICI-induced T1DM. Further research into its pathophysiology will improve management and possibly prevent this burdensome complication.

Titel:	Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?
Autor/in / Beteiligte Person:	Kyriacou, A ; Melson, E ; Chen, W ; Kempegowda, P
Link:	Full Text Finder (Volltext)
Zeitschrift:	Clinical medicine (London, England), Jg. 20 (2020-07-01), Heft 4, S. 417-423
Veröffentlichung:	2024- : [Oxford] : Elsevier Ltd. ; <i>Original Publication</i>: London : The College, c2001-, 2020
Medientyp:	academicJournal
ISSN:	1473-4893 (electronic)
DOI:	10.7861/clinmed.2020-0054
Schlagwort:	Antibodies, Monoclonal, Humanized Humans Immune Checkpoint Inhibitors Antineoplastic Agents Diabetes Mellitus, Type 1 chemically induced Diabetes Mellitus, Type 1 drug therapy Endocrine System Diseases
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Review Language: English [Clin Med (Lond)] 2020 Jul; Vol. 20 (4), pp. 417-423. MeSH Terms: Antineoplastic Agents* ; Diabetes Mellitus, Type 1* / chemically induced ; Diabetes Mellitus, Type 1* / drug therapy ; Endocrine System Diseases* ; Antibodies, Monoclonal, Humanized ; Humans ; Immune Checkpoint Inhibitors References: J Thorac Oncol. 2017 Nov;12(11):e182-e184. (PMID: 29074210) ; BMJ Open Diabetes Res Care. 2019 Feb 13;7(1):e000591. (PMID: 30899528) ; Eur J Dermatol. 2017 Apr 1;27(2):184-185. (PMID: 27934619) ; J Immunother Cancer. 2017 Dec 19;5(1):97. (PMID: 29254501) ; J Immunother Cancer. 2017 May 16;5:40. (PMID: 28515940) ; Am J Gastroenterol. 2000 Oct;95(10):2795-800. (PMID: 11051350) ; Diabetes Care. 2015 Apr;38(4):e55-7. (PMID: 25805871) ; J La State Med Soc. 2017 Mar-Apr;169(2):49. (PMID: 28414668) ; J Clin Endocrinol Metab. 2018 Sep 1;103(9):3144-3154. (PMID: 29955867) ; Diabetes Care. 2015 Sep;38(9):e137-8. (PMID: 26116720) ; Tohoku J Exp Med. 2016;239(2):155-8. (PMID: 27297738) ; J Dermatol. 2017 May;44(5):605-606. (PMID: 27334247) ; Nat Rev Endocrinol. 2017 Apr;13(4):195-207. (PMID: 28106152) ; Adv Emerg Nurs J. 2018 Jan/Mar;40(1):16-20. (PMID: 29384770) ; Cancer Immunol Immunother. 2016 Jun;65(6):765-7. (PMID: 27067877) ; Int J Hematol. 2017 Mar;105(3):383-386. (PMID: 27696192) ; Tohoku J Exp Med. 2018;244(1):33-40. (PMID: 29343652) ; JAMA Oncol. 2018 Feb 1;4(2):173-182. (PMID: 28973656) ; N Engl J Med. 2012 Jun 28;366(26):2455-65. (PMID: 22658128) ; Ann Oncol. 2017 Jan 1;28(1):191-192. (PMID: 28043983) ; J Natl Cancer Inst. 2016 Dec 31;109(4):. (PMID: 28040701) ; J Diabetes Investig. 2018 Mar;9(2):448-449. (PMID: 29504279) ; Case Rep Oncol. 2017 Mar 2;10(1):230-234. (PMID: 28611636) ; J Clin Oncol. 2018 Jun 10;36(17):1714-1768. (PMID: 29442540) ; Melanoma Res. 2017 Oct;27(5):524-525. (PMID: 28858175) ; Acta Diabetol. 2019 Apr;56(4):441-448. (PMID: 30284618) ; Int J Cancer. 2017 Dec 15;141(12):2562-2570. (PMID: 28833119) ; Immunotherapy. 2017 Sep;9(10):797-804. (PMID: 28877632) ; Cancer Immunol Immunother. 2015 Jun;64(6):765-7. (PMID: 25828465) ; Case Rep Oncol. 2017 Oct 17;10(3):897-909. (PMID: 29279690) ; Acta Diabetol. 2019 Apr;56(4):489-490. (PMID: 30361845) ; Cancer Immunol Immunother. 2017 Jan;66(1):25-32. (PMID: 27761609) ; Intern Med. 2018 Jul 15;57(14):2029-2034. (PMID: 29491310) ; J Diabetes Investig. 2016 Nov;7(6):915-918. (PMID: 27181090) ; Diabetes Care. 2018 Mar;41(3):638-639. (PMID: 29463667) ; J Immunother. 2017 Jul/Aug;40(6):249-251. (PMID: 28557813) ; J Diabetes Investig. 2012 Dec 20;3(6):536-9. (PMID: 24843620) ; J Thorac Oncol. 2017 May;12(5):e41-e43. (PMID: 28017788) ; Eur J Cancer. 2016 Jun;60:190-209. (PMID: 27085692) ; BMJ Case Rep. 2018 Jan 29;2018:. (PMID: 29378735) ; Endocrinol Diabetes Metab Case Rep. 2018 Mar 21;2018:. (PMID: 29576870) ; N Engl J Med. 2000 Feb 3;342(5):301-7. (PMID: 10655528) ; J Immunother Cancer. 2016 Dec 20;4:89. (PMID: 28031819) ; Diabetes Care. 2015 Nov;38(11):e182-3. (PMID: 26310693) ; Ther Adv Endocrinol Metab. 2019 Dec 25;10:2042018819896182. (PMID: 31903179) ; Acta Diabetol. 2016 Oct;53(5):853-6. (PMID: 27300348) ; Eur J Endocrinol. 2018 Feb;178(2):173-180. (PMID: 29187509) ; J Diabetes Investig. 2017 Nov;8(6):798-799. (PMID: 29098805) ; Diabetes. 2018 Aug;67(8):1471-1480. (PMID: 29937434) ; J Diabetes Investig. 2018 Mar;9(2):438-441. (PMID: 28418115) ; Cancer Immunol Immunother. 2017 Nov;66(11):1399-1410. (PMID: 28634815) ; Acta Derm Venereol. 2017 Mar 10;97(3):408-409. (PMID: 27377178) ; Diabetes Care. 2003 Aug;26(8):2345-52. (PMID: 12882860) ; Target Oncol. 2017 Apr;12(2):235-241. (PMID: 28255845) ; Melanoma Res. 2018 Apr;28(2):159-160. (PMID: 29485550) ; Endocrinol Diabetes Nutr. 2017 May;64(5):272-273. (PMID: 29056250) ; J Immunol. 2009 Aug 15;183(4):2277-85. (PMID: 19635924) ; Diabetes Metab. 2017 Feb;43(1):86-88. (PMID: 27291328) ; Diabet Med. 2019 Sep;36(9):1075-1081. (PMID: 31199005) ; Eur Med J Diabetes. 2019 Mar;4(1):89-98. (PMID: 31069088) ; Endocrinol Diabetes Metab Case Rep. 2018 Mar 28;2018:. (PMID: 29623210) ; Diabetologia. 2000 Oct;43(10):1332. (PMID: 11079755) ; Hormones (Athens). 2016 Apr;15(2):303-306. (PMID: 27376434) ; J Immunother. 2018 Jun;41(5):232-240. (PMID: 29481423) ; Immunotherapy. 2017 Jun;9(7):531-535. (PMID: 28595520) ; Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):e143-e146. (PMID: 29342442) ; BMJ Case Rep. 2016 Nov 23;2016:. (PMID: 27881588) Contributed Indexing: Keywords: Diabetes; ICI-induced; immune pathogenesis; immunopathology; insulin-deficient; type 1 Substance Nomenclature: 0 (Antibodies, Monoclonal, Humanized) ; 0 (Antineoplastic Agents) ; 0 (Immune Checkpoint Inhibitors) Entry Date(s): Date Created: 20200718 Date Completed: 20210514 Latest Revision: 20240426 Update Code: 20240426 PubMed Central ID: PMC7385772

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?